PI Trade Names and Active Ingredients containing Arixtra. 1 Documents available. Need more information on a product? Search the Australian Register of. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 mg04 mL mgmL75 mg06 mL injection of Arixtra mg in young healthy subjects are provided in Table 1 below: . Arixtra mg once daily following hip fracture surgery, patients were.

Author: Gardagis Dosida
Country: Eritrea
Language: English (Spanish)
Genre: Relationship
Published (Last): 22 August 2004
Pages: 165
PDF File Size: 15.7 Mb
ePub File Size: 9.61 Mb
ISBN: 957-6-39269-569-2
Downloads: 75725
Price: Free* [*Free Regsitration Required]
Uploader: Gor

For patients undergoing hip surgery extended DVT prophylaxis is indicated up to 24 additional days; up to a total 32 of days peri-operative and extended prophylaxis has been tolerated during clinical trials. As with other antithrombotic agents, fondaparinux should be used with extreme caution in patients with an increased risk of hemorrhage.

Clinical practice guidelines suggest alternative anticoagulants, such as warfarin, unfractionated heparin, or low molecular weight heparin, rather than fondaparinux during breast-feeding. Minor Agents, such as anticoagulants, that agixtra clotting could decrease the efficacy of photosensitizing agents used in photodynamic therapy.

Arixtra (fondaparinux sodium) dose, indications, adverse effects, interactions from

No further data regarding the safety and efficacy of this route of administration are available. Consider delaying the onset of defibrotide treatment arixra the effects of the antithrombotic agent have abated.

Patients should be instructed to arixtraa for signs and symptoms of bleeding while taking an SSRI with an arixtar medication. During clinical prophylaxis trials in patients with hip fracture, or hip or knee replacement surgery, major bleeding occurred in 1. Moderate Anticoagulants may alter sodium iodide I pharmacokinetics and dynamics for up to 1 week after administrations.

Moderate Monitor for evidence of bleeding if coadministration of dasatinib and anticoagulants is necessary. Additionally, nandrolone decanoate may generate a pharmacodynamic interaction with warfarin by independently affecting the activity of circulating coagulation proteins. Patients on anticoagulants should be monitored for changes in response to anticoagulation therapy if cilostazol is administered concurrently.


Wipe the surface of the injection site with an alcohol swab. Safe zrixtra effective use of fondaparinux in neonates, infants, and children has not been established. An antidote to reverse bleeding effects of fondaparinux is not available; however, one is under investigation. There was no statistically significant difference in INRs between the placebo or treatment period within each group. Androgens, such as testosterone, increase the synthesis of several anticoagulant and fibrinolytic proteins.

Moderate Due to the thrombocytopenic effects of pyrimidine analogs, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants. In addition, the bleeding risk for spinal or epidural hematomas, which may result in permanent arixttra long-term paralysis, may be greater with postoperative use of indwelling epidural catheters, a history of traumatic or repeated epidural or spinal puncture, a history of spinal deformity, a history of spinal surgery, or concomitant use of other drugs affecting hemostasis, such as NSAIDs, platelet inhibitors, or other anticoagulants.

PDR Search

Subgroup analyses indicate that fondaparinux therapy was beneficial in patients receiving thrombolytics and in those that did not receive any type of reperfusion treatment; however, in those patients undergoing primary PCI, a benefit with fondaparinux was not seen.

Thrombocytopenia has occurred with fondaparinux. Other intramuscular injections should be administered cautiously to patients receiving fondaparinux.

Major Danazol can decrease hepatic synthesis of procoagulant factors, increasing the possibility of bleeding when used concurrently pii anticoagulants. Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs.

In clinical trials, there have been reports of intracranial bleeding, including fatalities, in HIV infected patients receiving afixtra as part of combination antiretroviral therapy. Prothrombin Complex Concentrate, Human: The usual duration of administration is 5 to 9 days; up to 11 additional days has been tolerated. Moderate Platelet aggregation may be impaired by vortioxetine due to platelet serotonin arixyra, possibly increasing the risk of a bleeding complication e.


Bleeding events related to drugs that inhibit serotonin reuptake have ranged from ecchymosis to life-threatening hemorrhages.

The usual duration of administration is 5 to 9 days; up to 10 days has been administered. The GUSTO V study evaluated reduced-dose reteplase aritxra combination with full dose abciximab, in comparison to full dose reteplase alone in patients with acute myocardial infarction MI ; all patients received concurrent aspirin and heparin therapy.

Mylan Worldwide

arixtar The bleeding risk is significantly increased with concurrent abciximab and thrombolytic therapy; the risks of combination therapy should be weighed against the potential benefits.

Selective serotonin reuptake inhibitors: Significant binding to other proteins, including platelet factor 4 or red blood cells does not occur. Monitor clinical and laboratory response closely during concurrent use. Patients may be at increased risk of bleeding if anagrelide is administered with aspirin. Major Platelet aggregation may be impaired by duloxetine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.

Moderate Aruxtra use of topiramate and anticoagulants e. Moderate Telavancin has no effect on coagulation or platelet aggregation; however, caution is advised when administering telavancin concurrently with anticoagulants as telavancin may arixtraa with laboratory tests used in monitoring these medications.

Patients should be instructed to monitor for signs and symptoms of bleeding while taking vortioxetine concurrently with anticoagulants and to promptly report any bleeding events to the practitioner. Inhibits factor Xa but not factor IIa thrombin.